RBR-6jhtvfy尚未招募不适用
Impact of Natalizumab use in patients with Multiple Sclerosis
Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição da Universidade Federal de Mato Grosso do Sul0 个研究点开始时间: 2022年5月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18Y 至 0（—）
入选标准
- •Patients diagnosed with Multiple Sclerosis, according to the 10th edition of the International Code of Diseases (ICD 10), classified as G35, diagnosed according to revised and adapted McDonalds criteria will be included in the research; of both sexes; aged over 18 years; who have been on natalizumab treatment for at least 3 months, presenting at least one Expanded Disability Status Scale (EDSS) assessment prior to the use of natalizumab and a subsequent assessment
排除标准
- •Individuals with cognitive alterations that make it difficult to remember facts related to their disease and to understand the research will be excluded, as well as those who do not meet the inclusion criteria
研究者
相似试验
已完成
不适用
The effect of natalizumab treatment on functional adaptation in multiple sclerosis (MS)MS1000381610012303Multiple SclerosisNL-OMON40114Vrije Universiteit Medisch Centrum60
已完成
2 期
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)Relapsing-Remitting Multiple SclerosisNCT01405820Biogen290
已完成
4 期
Towards personalized dosing of natalizumab in multiple sclerosisMS10012303multiple sclerosisNL-OMON43550Vrije Universiteit Medisch Centrum60
进行中（未招募）
1 期
Reduce the number of natalizumab infusions in patients with multiple sclerosisMedDRA version: 18.1Level: LLTClassification code 10070425Term: Multiple sclerosis exacerbationSystem Organ Class: 100000004852multiple sclerosisEUCTR2016-000345-31-NLVU medical center60
已完成
不适用
Clinical effects of treatment with omalizumab in patients with asthmaBronchial asthmaJPRN-UMIN000002765Atami Hospital International University of Health and Welfare40